Progressive resistance exercise to be studied for muscle mass preservation during tirzepatide-induced weight loss

Obesity is a global health challenge, often managed with pharmacological interventions like tirzepatide, which effectively induces significant weight loss. However, a common drawback of rapid weight loss, including that induced by GLP-1/GIP agonists, is the concomitant loss of lean muscle mass, potentially leading to sarcopenia and impaired physical function. Preserving muscle mass is crucial for metabolic health, strength, and long-term weight management. This study addresses the critical gap in understanding how structured progressive resistance exercise can mitigate muscle loss and enhance functional outcomes in individuals undergoing tirzepatide treatment.

This randomized parallel group study will enroll overweight and obese females. Participants will receive tirzepatide over 20 weeks, starting at 2.5mg/week and titrating +2.5mg/week every four weeks. One group (GLP-1 +EXC) will also undertake a progressive resistance exercise program. The study aims to compare the effects on muscle mass and physical function between the exercise and non-exercise groups during tirzepatide-induced weight loss. Primary endpoints include changes in muscle mass and physical function.